New findings reveal how an RNA demethylase fuels age-associated B cell expansion in SLE—and how targeting it could offer new therapy
Unraveling the Mystery Behind Lupus-Driving B Cells
Systemic lupus erythematosus (SLE) is an autoimmune disease marked by autoantibody production and organ damage, often driven by the expansion of age-associated B cells (ABCs). While ABCs are known to contribute to SLE progression, what fuels their expansion has remained unclear—until now.
A new study by Zeng et al. identifies the RNA demethylase FTO (fat mass and obesity-associated protein) as a central regulator of ABC formation and activity in both human patients and mouse models of lupus.
- FTO expression is elevated in ABCs from lupus patients and correlates with renal immune damage.
- Overexpression of FTO worsens lupus symptoms, while deleting FTO in mice reduces disease severity.
TLR7 Signaling Turns on FTO in Autoimmune B Cells
The study uncovers that TLR7 (Toll-like receptor 7)—a known autoimmunity trigger—activates FTO expression through the MyD88 signaling pathway, setting off a cascade that promotes ABC expansion.
- TLR7 is typically activated by viral RNA or endogenous nucleic acids in SLE.
- This activation leads to elevated FTO, priming B cells for differentiation into ABCs.
FTO Drives Metabolic Changes That Enable Autoimmunity
FTO promotes ABC differentiation by regulating the mRNA of ATP6V1G1, a subunit of the vacuolar H⁺-ATPase (V-ATPase). This occurs through m6A RNA demethylation, a process that modifies RNA stability and translation.
- V-ATPase is essential for lysosomal autophagy, the cellular process that clears damaged components.
- FTO boosts ATP6V1G1 expression, maintaining autophagy and mitochondrial quality control.
When FTO is deleted or inhibited:
- Autophagy is impaired, leading to the accumulation of damaged mitochondria.
- Mitochondrial dysfunction emerges, with reduced oxidative phosphorylation and elevated ROS (reactive oxygen species).
- ABC differentiation is disrupted, largely due to poor responsiveness to IL-12, a cytokine crucial for their development.
Targeting the FTO Pathway: A New Therapeutic Avenue?
By linking TLR7 signaling to mitochondrial health through FTO, this study provides a mechanistic bridge between innate immune activation and B cell-driven autoimmunity in SLE.
- The TLR7–FTO–ATP6V1G1 axis shapes ABC function at both the epigenetic and metabolic levels.
- Targeting FTO or its downstream effectors may offer selective ways to suppress harmful ABCs without broadly shutting down the immune system.
This opens the door to potential precision therapies that intervene at a key regulatory checkpoint in lupus pathology.
FTO, an RNA demethylase, drives age-associated B cell (ABC) expansion in lupus by linking TLR7 signaling to mitochondrial and autophagic regulation. Inhibiting FTO impairs ABC differentiation and autoimmunity, offering a promising therapeutic target for systemic lupus erythematosus (SLE).
